Below is a report that DML News gives a 4 OUT OF 4 STARS trustworthiness rating. We base this rating on the following criteria:

  • Provides named sources
  • Reported by more than one notable outlet
  • Does not insert opinion or leading words
  • Includes supporting video, direct statements, or photos

Click here to read more about our rating system.

As the most reliable and balanced news aggregation service on the internet, DML News offers the following information published by WASHINGTONEXAMINER.COM:

Health and Human Services has terminated an agreement with a fetal tissue research facility that was providing fetal tissue to the Food and Drug Administration.

HHS said late Monday that it canceled the contract with the company, Advanced Bioscience Resources, because it didn’t include “appropriate protections” for fetal tissue procurement. The agency’s statement did not go into specifics.

The article goes on to state the following:

The agency said in a statement that it has “initiated a comprehensive review of all research involving fetal tissue to ensure consistency with statutes and regulations governing such research.”

HHS released the following statement:

“After a recent review of a contract between Advanced Bioscience Resources, Inc. and the Food and Drug Administration to provide human fetal tissue to develop testing protocols, HHS was not sufficiently assured that the contract included the appropriate protections applicable to fetal tissue research or met all other procurement requirements. As a result, that contract has been terminated, and HHS is now conducting an audit of all acquisitions involving human fetal tissue to ensure conformity with procurement and human fetal tissue research laws and regulations. In addition, HHS has initiated a comprehensive review of all research involving fetal tissue to ensure consistency with statutes and regulations governing such research, and to ensure the adequacy of procedures and oversight of this research in light of the serious regulatory, moral, and ethical considerations involved. Finally, HHS is continuing to review whether adequate alternatives exist to the use of human fetal tissue in HHS funded research and will ensure that efforts to develop such alternatives are funded and accelerated.”

To weigh in on this information provided by WASHINGTONEXAMINER.COM, engage in our LIVE CHAT below. Scroll down.